Related references
Note: Only part of the references are listed.Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural Mesothelioma
Tomer Meirson et al.
JAMA NETWORK OPEN (2022)
Phase 1 study of 2 high dose intensity schedules of the pan-Notch inhibitor crenigacestat (LY3039478) in combination with prednisone in patients with advanced or metastatic cancer
Analia Azaro et al.
INVESTIGATIONAL NEW DRUGS (2021)
A Phase II and Pharmacodynamic Trial of RO4929097 for Patients With Recurrent/Progressive Glioblastoma
David M. Peereboom et al.
NEUROSURGERY (2021)
Pleural mesothelioma (PM)-The status of systemic therapy
Wanyuan Cui et al.
CANCER TREATMENT REVIEWS (2021)
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
Paul Baas et al.
LANCET (2021)
Gamma Secretase Inhibitors in Cancer: A Current Perspective on Clinical Performance
Tyler R. McCaw et al.
ONCOLOGIST (2021)
A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors
Analia Azaro et al.
INVESTIGATIONAL NEW DRUGS (2021)
Liquid Biopsies from Pleural Effusions and Plasma from Patients with Malignant Pleural Mesothelioma: A Feasibility Study
Gabriele Moretti et al.
CANCERS (2021)
Hyperthermic Intrathoracic Chemoperfusion for Malignant Pleural Mesothelioma: Systematic Review and Meta-Analysis
Tommi Jarvinen et al.
CANCERS (2021)
Phase 1 study to evaluate Crenigacestat (LY3039478) in combination with dexamethasone in patients with T-cell acute lymphoblastic leukemia and lymphoma
Gautam Borthakur et al.
CANCER (2021)
Substrate recognition and processing by γ-secretase
Michael S. Wolfe
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2020)
CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma
Duo Xu et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Metabolic rewiring and redox alterations in malignant pleural mesothelioma
Loredana Urso et al.
BRITISH JOURNAL OF CANCER (2020)
Survival of malignant mesothelioma and other rare thoracic cancers in Germany and the United States: A population-based study
Eunice Sirri et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer
Sagar Sardesai et al.
INVESTIGATIONAL NEW DRUGS (2020)
The Role of Neoadjuvant Chemotherapy in Patients With Resectable Malignant Pleural Mesothelioma-An Institutional and National Analysis
Soraya L. Voigt et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
Overcoming Drug Resistance by Taking Advantage of Physical Principles: Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)
Giorgi Nadiradze et al.
CANCERS (2020)
Manipulating microRNAs for the Treatment of Malignant Pleural Mesothelioma: Past, Present and Future
Glen Reid et al.
FRONTIERS IN ONCOLOGY (2020)
Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives
Steven G. Gray et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2020)
Roles and mechanisms of alternative splicing in cancer - implications for care
Sophie C. Bonnal et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Extracellular vesicles as biomarkers in malignant pleural mesothelioma: A review
Tamkin Ahmadzada et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2020)
Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds
Giovanna Li Petri et al.
BRITISH JOURNAL OF CANCER (2020)
Specific Targeting of Notch Ligand-Receptor Interactions to Modulate Immune Responses: A Review of Clinical and Preclinical Findings
Mounika U. L. Goruganthu et al.
FRONTIERS IN IMMUNOLOGY (2020)
Top Notch Targeting Strategies in Cancer: A Detailed Overview of Recent Insights and Current Perspectives
Gillian Moore et al.
CELLS (2020)
Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in
Anna K Nowak et al.
LANCET ONCOLOGY (2020)
Non-canonical Notch Signaling Regulates Actin Remodeling in Cell Migration by Activating PI3K/AKT/Cdc42 Pathway
Lei Liu et al.
FRONTIERS IN PHARMACOLOGY (2019)
Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives
Ilaria Cavallari et al.
FRONTIERS IN ONCOLOGY (2019)
LBA91_PRA multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
S Popat et al.
ANNALS OF ONCOLOGY (2019)
New avenues in pancreatic cancer: exploiting microRNAs as predictive biomarkers and new approaches to target aberrant metabolism
Mjriam Capula et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2019)
BAP1 Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment
Alice Guazzelli et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors
David C. Smith et al.
INVESTIGATIONAL NEW DRUGS (2019)
Testicular Mesothelioma: An Analysis of Epidemiology, Patient Outcomes, and Prognostic Factors
Azadeh Nazemi et al.
UROLOGY (2019)
Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma
Rocco Sciarrillo et al.
EBIOMEDICINE (2019)
Epidemiology of Mesothelioma
Domenica Cavone et al.
ENVIRONMENTS (2019)
Extracellular vesicles in cancer - implications for future improvements in cancer care
Rong Xu et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Progress and challenges in Mesothelioma: From bench to bedside
Kevin G. Blyth et al.
RESPIRATORY MEDICINE (2018)
Novel drug-resistance mechanisms of pemetrexed-treated non-small cell lung cancer
Ryosuke Tanino et al.
Oncotarget (2018)
Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma
Douae Bensaid et al.
CLINICAL EPIGENETICS (2018)
Hypoxia promotes acquisition of aggressive phenotypes in human malignant mesothelioma
Myung-Chul Kim et al.
BMC CANCER (2018)
FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer
Kelly M. Kreitzburg et al.
CANCER LETTERS (2018)
Scientific Advances and New Frontiers in Mesothelioma Therapeutics
Luciano Mutti et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation
Jacob O'Brien et al.
FRONTIERS IN ENDOCRINOLOGY (2018)
Synergistic antitumor effect of a γ-secretase inhibitor PF-03084014 and sorafenib in hepatocellular carcinoma
Xuran Yang et al.
Oncotarget (2018)
Current chemotherapy strategies in malignant pleural mesothelioma
Cornedine Jannette de Gooijer et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2018)
Development and characterization of cationic solid lipid nanoparticles for co-delivery of pemetrexed and miR-21 antisense oligonucleotide to glioblastoma cells
Berrin Kucukturkmen et al.
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY (2018)
Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism
Rihan El Bezawy et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma
Steven C. Kao et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study
Nico van Zandwijk et al.
LANCET ONCOLOGY (2017)
Notch Inhibitor PF-03084014 Inhibits Hepatocellular Carcinoma Growth and Metastasis via Suppression of Cancer Stemness due to Reduced Activation of Notch1-Stat3
Chuan Xing Wu et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden
Meredith L. Stone et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
MicroRNA-31 Regulates Chemosensitivity in Malignant Pleural Mesothelioma
Hannah L. Moody et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2017)
Plasmatic extracellular vesicle microRNAs in malignant pleural mesothelioma and asbestos-exposed subjects suggest a 2-miRNA signature as potential biomarker of disease
Tommaso Cavalleri et al.
PLOS ONE (2017)
Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism
Chiara De Santi et al.
SCIENTIFIC REPORTS (2017)
MicroRNA Expression in Malignant Pleural Mesothelioma and Asbestosis: A Pilot Study
Paola Mozzoni et al.
DISEASE MARKERS (2017)
Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer
Michael J. Topper et al.
CELL (2017)
Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: clinical evidence and new pharmacological tools
E. Giovannetti et al.
ANNALS OF ONCOLOGY (2017)
miRNAs: micro-managers of anticancer combination therapies
Judy R. van Beijnum et al.
ANGIOGENESIS (2017)
Targeting the epigenome in malignant pleural mesothelioma
Kaitlin C. McLoughlin et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2017)
Circulating miR-132-3p as a Candidate Diagnostic Biomarker for Malignant Mesothelioma
Daniel G. Weber et al.
DISEASE MARKERS (2017)
Young investigator challenge: MicroRNA-21/MicroRNA-126 profiling as a novel tool for the diagnosis of malignant mesothelioma in pleural effusion cytology
Rocco Cappellesso et al.
CANCER CYTOPATHOLOGY (2016)
Differential microRNA expression profiling of mesothelioma and expression analysis of miR-1 and miR-214 in mesothelioma
Vishwa Jeet Amatya et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
Hypoxia-inducible factors: a central link between inflammation and cancer
Daniel Triner et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
Raphael Bueno et al.
NATURE GENETICS (2016)
Characterisation of Mesothelioma-Initiating Cells and Their Susceptibility to Anti-Cancer Agents (vol 10, e0119549, 2015)
Elham Alizadeh Pasdar et al.
PLOS ONE (2016)
Small Molecule Modulators of Pre-mRNA Splicing in Cancer Therapy
Maayan Salton et al.
TRENDS IN MOLECULAR MEDICINE (2016)
Inflammation and Notch signaling: a crosstalk with opposite effects on tumorigenesis
Chiara Fazio et al.
CELL DEATH & DISEASE (2016)
Tumor suppressor microRNAs are downregulated in myelodysplastic syndrome with spliceosome mutations
Derya Aslan et al.
ONCOTARGET (2016)
Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers
Ilaria Bononi et al.
ONCOTARGET (2016)
The emerging role of FTY720 (Fingolimod) in cancer treatment
Christopher White et al.
ONCOTARGET (2016)
An Integrated Analysis of the Genome-Wide Profiles of DNA Methylation and mRNA Expression Defining the Side Population of a Human Malignant Mesothelioma Cell Line
Myung-Chul Kim et al.
JOURNAL OF CANCER (2016)
A microRNA isolation method from clinical samples
Sepideh Zununi Vahed et al.
BIOIMPACTS (2016)
A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia
Ivan Diaz-Padilla et al.
GYNECOLOGIC ONCOLOGY (2015)
Loss of miR-223 and JNK Signaling Contribute to Elevated Stathmin in Malignant Pleural Mesothelioma
Kimberly A. Birnie et al.
MOLECULAR CANCER RESEARCH (2015)
The spliceosome is a therapeutic vulnerability in MYC-driven cancer
Tiffany Y. -T. Hsu et al.
NATURE (2015)
Loss of BAP1 function leads to EZH2-dependent transformation
Lindsay M. LaFave et al.
NATURE MEDICINE (2015)
Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update
Naoko Takebe et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Bioanalytical techniques for detecting biomarkers of response to human asbestos exposure
Clementina Mesaros et al.
BIOANALYSIS (2015)
miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma
Marissa Williams et al.
ONCOTARGET (2015)
HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade
David M. Woods et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Phase 2 Study of RO4929097, a Gamma-Secretase Inhibitor, in Metastatic Melanoma: SWOG 0933
Sylvia M. Lee et al.
CANCER (2015)
Pre-mRNA splicing in cancer: the relevance in oncogenesis, treatment and drug resistance
Anna Wojtuszkiewicz et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2015)
MiR-Score: A novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma
Michaela B. Kirschner et al.
MOLECULAR ONCOLOGY (2015)
BAP1 Missense Mutation c.2054 A>T (p.E685V) Completely Disrupts Normal Splicing through Creation of a Novel 5′ Splice Site in a Human Mesothelioma Cell Line
Arianne Morrison et al.
PLOS ONE (2015)
Cisplatin-resistant cells in malignant pleural mesothelioma cell lines show ALDHhighCD44+ phenotype and sphere-forming capacity
Lourdes Cortes-Dericks et al.
BMC CANCER (2014)
Transcriptional regulation by hypoxia inducible factors
Veronica L. Dengler et al.
CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY (2014)
Coherence between Cellular Responses and in Vitro Splicing Inhibition for the Anti-tumor Drug Pladienolide B and Its Analogs
Kerstin A. Effenberger et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Dll4-Notch signaling in regulation of tumor angiogenesis
Zhaoguo Liu et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2014)
Diagnostic Potential of miR-126, miR-143, miR-145, and miR-652 in Malignant Pleural Mesothelioma
Morten Andersen et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2014)
Cisplatin-induced epigenetic activation of miR-34a sensitizes bladder cancer cells to chemotherapy
Heng Li et al.
MOLECULAR CANCER (2014)
Upregulation of microRNA-31 associates with a poor prognosis of malignant pleural mesothelioma with sarcomatoid component
Shinji Matsumoto et al.
MEDICAL ONCOLOGY (2014)
miR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma
Kazuo Yamamoto et al.
ONCOLOGY REPORTS (2014)
Small RNA combination therapy for lung cancer
Wen Xue et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Advances in the management of peritoneal mesothelioma
Ali Raza et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Critical appraisal of pemetrexed in the treatment of NSCLC and metastatic pulmonary nodules
Xin Li et al.
ONCOTARGETS AND THERAPY (2014)
Molecular pathogenesis of malignant mesothelioma
Yoshitaka Sekido
CARCINOGENESIS (2013)
miR-1 Induces Growth Arrest and Apoptosis in Malignant Mesothelioma
Yue Xu et al.
CHEST (2013)
Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma
Ioannis Pantazopoulos et al.
EUROPEAN RESPIRATORY JOURNAL (2013)
The role of epigenetics in malignant pleural mesothelioma
Fabian Vandermeers et al.
LUNG CANCER (2013)
The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma
Takayuki Muraoka et al.
LUNG CANCER (2013)
The Cancer Genome Atlas Pan-Cancer analysis project
John N. Weinstein et al.
NATURE GENETICS (2013)
Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma
H. Richard Alexander et al.
SURGERY (2013)
Synergistic Effect of the γ-Secretase Inhibitor PF-03084014 and Docetaxel in Breast Cancer Models
Cathy C. Zhang et al.
STEM CELLS TRANSLATIONAL MEDICINE (2013)
Cancer stem cells
Jayanth Panyam
DRUG DELIVERY AND TRANSLATIONAL RESEARCH (2013)
A phase II study of RO4929097 in metastatic colorectal cancer
Jonathan R. Strosberg et al.
EUROPEAN JOURNAL OF CANCER (2012)
aV integrins and TGF-ß-induced EMT: a circle of regulation
Fahmy A. Mamuya et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2012)
Increased Circulating miR-625-3p A Potential Biomarker for Patients With Malignant Pleural Mesothelioma
Michaela B. Kirschner et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Identification of miRNA-103 in the Cellular Fraction of Human Peripheral Blood as a Potential Biomarker for Malignant Mesothelioma - A Pilot Study
Daniel G. Weber et al.
PLOS ONE (2012)
Sphingosine Kinase 1 Is Required for Mesothelioma Cell Proliferation: Role of Histone Acetylation
Satish Kalari et al.
PLOS ONE (2012)
Multipotent Cancer Stem Cells Derived from Human Malignant Peritoneal Mesothelioma Promote Tumorigenesis
Sheelu Varghese et al.
PLOS ONE (2012)
Identification of cancer stem cell markers in human malignant mesothelioma cells
Farhana Ishrat Ghani et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2011)
EphrinA1 inhibits malignant mesothelioma tumor growth via let-7 microRNA-mediated repression of the RAS oncogene
N. Khodayari et al.
CANCER GENE THERAPY (2011)
Resuscitating Cancer Immunosurveillance: Selective Stimulation of DLL1-Notch Signaling in T cells Rescues T-cell Function and Inhibits Tumor Growth
Yuhui Huang et al.
CANCER RESEARCH (2011)
Epigenetic Silencing of MicroRNA-34b/c Plays an Important Role in the Pathogenesis of Malignant Pleural Mesothelioma
Takafumi Kubo et al.
CLINICAL CANCER RESEARCH (2011)
Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study
A. Scherpereel et al.
EUROPEAN RESPIRATORY JOURNAL (2011)
MicroRNAs-10a and-10b Contribute to Retinoic Acid-induced Differentiation of Neuroblastoma Cells and Target the Alternative Splicing Regulatory Factor SFRS1 (SF2/ASF)
Salvador Meseguer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
Tom Treasure et al.
LANCET ONCOLOGY (2011)
Onconase mediated NFKβ downregulation in malignant pleural mesothelioma
C. M. Goparaju et al.
ONCOGENE (2011)
Association of MiR-126 with Soluble Mesothelin-Related Peptides, a Marker for Malignant Mesothelioma
Lory Santarelli et al.
PLOS ONE (2011)
MicroRNA Signature of Malignant Mesothelioma with Potential Diagnostic and Prognostic Implications
Sara Busacca et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2010)
Cytoreductive Surgery with Intraperitoneal Hyperthermic Chemotherapy for Malignant Peritoneal Mesothelioma: Mitomycin Versus Cisplatin
Aaron U. Blackham et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Notch signaling: Emerging molecular targets for cancer therapy
Ling Yin et al.
BIOCHEMICAL PHARMACOLOGY (2010)
hsa-miR-29c*Is Linked to the Prognosis of Malignant Pleural Mesothelioma
Harvey I. Pass et al.
CANCER RESEARCH (2010)
Targeting Notch to Target Cancer Stem Cells
Antonio Pannuti et al.
CLINICAL CANCER RESEARCH (2010)
Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma
Gretchen V. Gee et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Pro-tumorigenic Effects of miR-31 Loss in Mesothelioma
Sergey V. Ivanov et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
MicroRNA (miRNA)-mediated Interaction between Leukemia/Lymphoma-related Factor (LRF) and Alternative Splicing Factor/Splicing Factor 2 (ASF/SF2) Affects Mouse Embryonic Fibroblast Senescence and Apoptosis
Lorena Verduci et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
A Diagnostic Assay Based on MicroRNA Expression Accurately Identifies Malignant Pleural Mesothelioma
Hila Benjamin et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2010)
Mesothelioma of the tunica vaginalis: a series of eight cases with uncertain malignant potential
Fadi Brimo et al.
MODERN PATHOLOGY (2010)
Hyperthermic intraperitoneal chemotherapy: Rationale and technique
Santiago Gonzalez-Moreno et al.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2010)
The Canonical Notch Signaling Pathway: Unfolding the Activation Mechanism
Raphael Kopan et al.
CELL (2009)
Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P
Robert J. Kreitman et al.
CLINICAL CANCER RESEARCH (2009)
The Deubiquitinating Enzyme BAP1 Regulates Cell Growth via Interaction with HCF-1
Yuichi J. Machida et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Association of C-Terminal Ubiquitin Hydrolase BRCA1-Associated Protein 1 with Cell Cycle Regulator Host Cell Factor 1
Shahram Misaghi et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
The impact of microRNAs and alternative splicing in pharmacogenomics
F. Passetti et al.
PHARMACOGENOMICS JOURNAL (2009)
Opposite Effects of Notch-1 and Notch-2 on Mesothelioma Cell Survival under Hypoxia Are Exerted through the Akt Pathway
Irene Graziani et al.
CANCER RESEARCH (2008)
Mesothelioma Epidemiology, Carcinogenesis, and Pathogenesis
Haining Yang et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2008)
Mesothelin targeted cancer immunotherapy
Raffit Hassan et al.
EUROPEAN JOURNAL OF CANCER (2008)
Modulation of Notch signaling by antibodies specific for the extracellular negative regulatory region of NOTCH3
Kang Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Airborne Particulate Matter and Human Health: Toxicological Assessment and Importance of Size and Composition of Particles for Oxidative Damage and Carcinogenic Mechanisms
ATHANASIOS VALAVANIDIS et al.
JOURNAL OF ENVIRONMENTAL SCIENCE AND HEALTH PART C-ENVIRONMENTAL CARCINOGENESIS & ECOTOXICOLOGY REVIEWS (2008)
miR-148 targets human DNMT3b protein coding region
Anja M. Duursma et al.
RNA (2008)
Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia
Teresa Palomero et al.
NATURE MEDICINE (2007)
Phase I study of SS1P a recombinant anti-mesothelin immunotoxin given as a bolus IV infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers
Raffit Hassan et al.
CLINICAL CANCER RESEARCH (2007)
The MicroRNA miR-124 promotes neuronal differentiation by triggering brain-specific alternative Pre-mRNA splicing
Eugene V. Makeyev et al.
MOLECULAR CELL (2007)
Selection of patients with colorectal peritoneal carcinomatosis for cytoreductive surgery and perioperative intraperitoneal chemotherapy
Tristan D. Yan et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
Promoter methylation of RASSF1A, RARβ and DAPK predict poor prognosis of patients with malignant mesothelioma
Juergen R. Fischer et al.
LUNG CANCER (2006)
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma
GL Ceresoli et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Expression and prognostic significance of hypoxia-inducible factor 1 alpha (HIF-1 alpha) in malignant pleural mesothelioma (MPM)
A Klabatsa et al.
LUNG CANCER (2006)
Hypoxia requires Notch signaling to maintain the undifferentiated cell state
MV Gustafsson et al.
DEVELOPMENTAL CELL (2005)
Integration of TGF-β/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition
J Zavadil et al.
EMBO JOURNAL (2004)
Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720
ML Allende et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
FTY720: Sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function
V Brinkmann et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2004)
γ-secretase:: proteasome of the membrane?
R Kopan et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
Mesothelin-family proteins and diagnosis of mesothelioma
BWS Robinson et al.
LANCET (2003)
Share Paper
